|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500108657 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-03 09:54:53 |
|
注册时间: Date of Registration: |
2025-09-03 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
一种新型吸引双极电凝装置在功能性内窥镜鼻窦手术治疗慢性鼻窦炎中的应用:一项初步的随机对照试验 |
|
Public title: |
A pilot randomized controlled trial on the application of a novel suction bipolar electrocautery device in functional endoscopic sinus surgery for the treatment of chronic rhinosinusitis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
吸引双极电凝在鼻内镜手术中的止血效果及安全性评价 |
|
Scientific title: |
Evaluation of the Hemostatic Efficacy and Safety of Suction Bipolar Electrocautery in Endoscopic Sinus Surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡俊英 |
研究负责人: |
刘锋 |
|
Applicant: |
Hu Junying |
Study leader: |
Liu Feng |
|
申请注册联系人电话: Applicant telephone: |
+86 178 7356 2564 |
研究负责人电话: Study leader's telephone: |
+86 189 8060 6340 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hujunying2001@163.com |
研究负责人电子邮件: Study leader's E-mail: |
alexliufeng@vip.163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市武侯区国学巷37号 |
研究负责人通讯地址: |
四川省成都市武侯区国学巷37号 |
|
Applicant address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
Study leader's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023年审(1578)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学研究伦理委员会 |
||
|
Name of the ethic committee: |
The Biomedical Ethics Review Committee of West China Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-09-27 00:00:00 |
||
|
伦理委员会联系人: |
邓绍林 |
||
|
Contact Name of the ethic committee: |
Deng Shaolin |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 3237 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxue Lane, Wuhou District, Chengdu, Sichuan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
Target disease: |
Chronic rhinosinusitis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究采用随机对照试验,比较新型吸引双极电凝装置与常规单极电凝止血方式在功能性内窥镜鼻窦手术治疗慢性鼻窦炎中的术后初步疗效差异。通过术后鼻窦通气情况、症状改善、鼻息肉复发率及术后并发症等,评估新装置在促进黏膜恢复、改善症状及提升生活质量方面的临床效果和安全性,为新技术的临床推广提供循证依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study is a randomized controlled trial designed to compare the preliminary postoperative efficacy of a novel suction bipolar electrocautery device with that of conventional monopolar electrocautery in functional endoscopic sinus surgery (FESS) for the treatment of chronic rhinosinusitis. Postoperative endoscopic scores and quality-of-life assessments will be used to evaluate the clinical efficacy and safety of the new device in promoting mucosal healing, alleviating symptoms, and improving patient quality of life, thereby providing evidence for its potential clinical application. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1) 年龄在18至75岁之间; (2) 根据《2020年欧洲鼻窦炎与鼻息肉立场文件(EPOS 2020)》诊断为慢性鼻窦炎(CRS),可伴有或不伴有鼻息肉; (3) 拟行首次功能性内窥镜鼻窦手术(FESS); (4) 术前鼻窦CT Lund-Mackay评分 ≥5 分; (5) 凝血功能正常(血小板计数、PT、APTT在参考范围内或临床可接受); (6) 在充分了解研究方案后,自愿签署知情同意书; (7) 近三个月内未参与其他临床试验。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Aged 18 to 75 years; (2) Diagnosed with chronic rhinosinusitis (CRS), with or without nasal polyps, in accordance with the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS 2020); (3) Scheduled for primary functional endoscopic sinus surgery (FESS); (4) Preoperative Lund-Mackay score >=5 on sinus CT; (5) Normal coagulation function (platelet count, PT, and APTT within reference ranges or clinically acceptable); (6) Provided written informed consent after fully understanding the study protocol; (7) No participation in other clinical trials within the past three months. |
||||||||||||||||||||||
|
排除标准: |
(1) 存在全麻或鼻内镜手术禁忌证; (2) 长期使用抗凝药物或其他影响凝血功能的药物; (3) 长期全身应用糖皮质激素; (4) 伴有重大系统性疾病,如免疫缺陷(如HIV感染或长期免疫抑制剂使用)、无法控制的高血压(≥160/100 mmHg,尽管应用≥3种药物治疗)、无法控制的糖尿病(HbA1c>9%)或活动性肺结核; (5) 术前三个月内放置鼻部药物洗脱支架; (6) 既往接受过鼻部手术(如鼻中隔成形术、鼻窦手术、下鼻甲手术); (7) 妊娠、哺乳或其他可能影响研究结局的生理状态; (8) 存在既往眼部结构性疾病(如青光眼、视神经萎缩、高度屈光不正)或眼科手术史。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) known contraindications to general anesthesia or nasal endoscopic surgery; (2) long-term use of anticoagulants or other medications affecting coagulation; (3) long-term systemic corticosteroid therapy; (4) major systemic diseases, including immunodeficiency (e.g., HIV infection or long-term immunosuppressant use), uncontrolled hypertension (>=160/100 mmHg despite >=3 medications), uncontrolled diabetes (HbA1c > 9%), or active pulmonary tuberculosis; (5) nasal drug-eluting stent placement within the past 3 months; (6) prior nasal surgeries (e.g., septoplasty, sinus surgery, turbinate surgery); (7) pregnancy, lactation, or other physiological conditions likely to affect outcomes; (8) pre-existing ocular structural diseases (e.g., glaucoma, optic atrophy, high refractive error) or history of eye surgery. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-09-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-12-13 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由一名独立研究助理使用 Excel 中的 RAND 函数生成计算机随机数字表。将32例患者按照1:1比例随机分配至试验组(吸引式双极电凝)与对照组(吸引式单极电凝),每组16例。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A computer-generated random number table was created using the Excel RAND function by an independent research assistant. 32 patients were randomized in a 1:1 ratio into the experimental group (suction bipolar electrocautery) and the control group (suction monopolar electrocautery), with 16 patients in each group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
患者:不知晓自身分组,实施单盲;术者:因器械外观差异,无法实施盲法;评估者:术后随访与疗效评估由另一名独立研究人员完成,其不知晓分组信息,确保评估盲法。 |
|
Blinding: |
Patients: Were blinded to their group assignment (single-blind design). Surgeon: Not blinded due to the visible differences between devices. Outcome assessor: Postoperative assessments were conducted by an independent assessor blinded to group allocation. |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究产生的原始数据将在研究完成并发表主要结果后予以共享,预计时间为主要研究结果发表后6个月内。共享的数据包括经匿名化处理的个体水平数据(如基线资料、随访数据、疗效与安全性评价指标),不包含可识别受试者个人信息。数据共享方式为:申请者可通过向研究负责人邮箱发出申请,经伦理审查及课题组批准后,签署数据使用协议后获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The anonymized individual-level data (including baseline information, follow-up data, efficacy and safety evaluation indicators) will be available within 6 months after publication of the main results. Personally identifiable information will not be shared. Data will be provided upon reasonable request via email to the principal investigator, subject to ethics review, approval by the study team, and signing of a data use agreement. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用纸质病例记录表和EXCEL软件进行数据采集和管理,由研究人员于术前、术中和术后定期填写。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data will be collected and managed using paper case report forms and Excel by investigators at preoperative, intraoperative, and postoperative stages. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |